Literature DB >> 11181141

No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection.

F N Lauw1, J T van Der Meer, J de Metz, S A Danner, T van Der Poll.   

Abstract

Two human immunodeficiency virus-infected patients with refractory disseminated Mycobacterium avium complex infection were treated with recombinant interferon-gamma (IFN-gamma) given subcutaneously for 3 and 4 months, respectively. Although both patients demonstrated some clinical improvement initially, IFN-gamma therapy did not produce sustained benefit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181141     DOI: 10.1086/318705

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Modulation of innate host factors by Mycobacterium avium complex in human macrophages includes interleukin 17.

Authors:  Nancy Vázquez; Sofia Rekka; Maria Gliozzi; Carl G Feng; Shoba Amarnath; Jan M Orenstein; Sharon M Wahl
Journal:  J Infect Dis       Date:  2012-08-28       Impact factor: 5.226

2.  Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Authors:  R Reljic; S O Clark; A Williams; G Falero-Diaz; M Singh; S Challacombe; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

3.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08

4.  Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.

Authors:  Jo Seddon; Sanjay Bhagani
Journal:  HIV AIDS (Auckl)       Date:  2011-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.